Merck & Co. already owns a stake in antibody-drug conjugate specialist Seagen. But now, the New Jersey pharma appears to want the whole thing.
The deal, as reported by The Wall Street Journal citing people familiar with the matter, could value Seagen at about $28 billion if it eventually comes through.
Merck and Seagen have been talking about the possibility for some time, and a deal isn’t imminent, the people told WSJ. The two could eventually opt for a marketing collaboration instead, some of those people told WSJ.
Merck may not be the only suitor, with others also eyeing the cancer-focused biotech, some of the people told WSJ.
Through a 2020 deal, Merck acquired 5 million shares of Seagen for $1 billion. The Big Pharma company also paid $600 million upfront for the biotech’s LIV-1-targeting antibody-drug conjugates (ADCs) including the most advanced ladiratuzumab vedotin.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Spanish Startup Association Slams Microsoft’s Cloud Practices
May 7, 2024 by
CPI
TikTok and ByteDance File Lawsuit Against US Law Mandating App Sale
May 7, 2024 by
CPI
Apollo, Sony Bid to Acquire Paramount Faces Regulatory Hurdles
May 7, 2024 by
CPI
Turkey Fines Meta $10.4 Million for Abusing Market Dominance
May 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI